References
- Bozzetti F, Cozzaglio L, Biganzoli E, et al (2002). Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. Clin Nutr, 21, 281-8. https://doi.org/10.1054/clnu.2002.0560
- Davis MP, Nouneh C (2000). Modern management of cancerrelated intestinal obstruction. Curr Opin Oncol, 2, 343-50.
- Hisanaga T, Shinjo T, Morita T, et al (2010). Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol, 40, 739-45. https://doi.org/10.1093/jjco/hyq048
- Khoo D, Hall E, Motson R, et al (1994). Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer, 30, 28-30. https://doi.org/10.1016/S0959-8049(05)80012-7
- Mercadante S, Ripamonti C, Casuccio A (2000). Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant bowel obstruction. Support Care Cancer, 8, 188-91. https://doi.org/10.1007/s005200050283
- Mercadante S, Ferrera P, Villari P, Marrazzo A (2004). Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage, 28, 412-16. https://doi.org/10.1016/j.jpainsymman.2004.01.007
- Mercadante S, Casuccio A, Mangione S (2007). Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage, 33, 217-23. https://doi.org/10.1016/j.jpainsymman.2006.06.014
- Mercadante S, Porzio G (2012). Octreotide for malignant bowel obstruction: Twenty years after. Clin Rev Oncol/Hematol, 83, 388-92. https://doi.org/10.1016/j.critrevonc.2011.12.006
- Mystakidou K, Tsilika E, Kalaidopoulou O, et al (2000). Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, doubleblind, controlled clinical trial. Anticancer Res, 22, 1187-92.
- O'Connor B, Creedon B (2011). Pharmacological treatment of bowel obstruction in cancer patients. Expert Opin Pharmacother, 12, 2205-14. https://doi.org/10.1517/14656566.2011.597382
- Philip J, Depczynski B (1997). The role of total parenteral nutrition for patients with irreversible bowel obstruction secondary to gynecological malignancy. J Pain Symptom Manage, 13, 104-11. https://doi.org/10.1016/S0885-3924(96)00269-2
- Ripamonti C, Mercadante S, Groff L, et al (2000). Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage, 19, 23-34. https://doi.org/10.1016/S0885-3924(99)00147-5
- Ripamonti C, Mercadante S (2005). Pathophysiology and management of malignant bowel obstruction. In: Doyle D, Hanks GW, McDonald N, Cherny N eds. Oxford textbook of palliative medicine, 3rd edition. Oxford University Press, New York. 496-506.
- Tuca A, Guell E, Martinez-Losada E, et al (2012). Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Management Res, 4, 159-69.
- WHO Handbook for Reporting Results of Cancer Treatment (1979). WHO, Geneva, 1979.
Cited by
- Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951